Clinical and demographic characteristics of pediatric Langerhans cell Histiocytosis samples
| Characteristics . | n (%) . |
|---|---|
| Total | 217 (100) |
| Sex | |
| Male | 128 (59.0) |
| Female | 89 (41.0) |
| Age at diagnosis, years; median [range] | 3.1 [0.07-13.6] |
| Mutation status | |
| Plasma cell-free | |
| BRAFV600E(+) | 63 (29.0) |
| BRAFV600E (−) | 154 (71.0) |
| Lesion sequence | |
| BRAFV600E (+) | 95 (43.8) |
| BRAFV600E (−) | 79 (36.4) |
| NA | 43 (19.8) |
| Clinical classification | |
| MS-high risk | 33 (15.2) |
| MS-low risk | 65 (30.0) |
| SS-low risk | 119 (54.8) |
| Treatment | |
| First-line therapy | 153 (70.5) |
| Second-line therapy | 11 (5.1) |
| Targeted therapy | 7 (3.2) |
| First-line + Second-line therapy | 22 (10.1) |
| Second-line + Targeted therapy | 3 (1.4) |
| First-line + Targeted therapy | 10 (4.6) |
| First-line + Second-line + Targeted therapy | 4 (1.9) |
| Without treatment | 7 (3.2) |
| Characteristics . | n (%) . |
|---|---|
| Total | 217 (100) |
| Sex | |
| Male | 128 (59.0) |
| Female | 89 (41.0) |
| Age at diagnosis, years; median [range] | 3.1 [0.07-13.6] |
| Mutation status | |
| Plasma cell-free | |
| BRAFV600E(+) | 63 (29.0) |
| BRAFV600E (−) | 154 (71.0) |
| Lesion sequence | |
| BRAFV600E (+) | 95 (43.8) |
| BRAFV600E (−) | 79 (36.4) |
| NA | 43 (19.8) |
| Clinical classification | |
| MS-high risk | 33 (15.2) |
| MS-low risk | 65 (30.0) |
| SS-low risk | 119 (54.8) |
| Treatment | |
| First-line therapy | 153 (70.5) |
| Second-line therapy | 11 (5.1) |
| Targeted therapy | 7 (3.2) |
| First-line + Second-line therapy | 22 (10.1) |
| Second-line + Targeted therapy | 3 (1.4) |
| First-line + Targeted therapy | 10 (4.6) |
| First-line + Second-line + Targeted therapy | 4 (1.9) |
| Without treatment | 7 (3.2) |
NA: Not available; SS: single-system; MS: multiple system.